Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 79 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 13910
Sealed predictions
- GALNT6 in dopamine neurons, braak-0.83 (p 0.006) → -0.03 (p 0.929)receipt 13917
Swarm cases
receipt 13917: GALNT6 in dopamine neurons, braak
- power
- full sample -0.49 (p 0.040, n 18), 95% CI -0.78 to -0.03. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.43 (p 0.075, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.51 (p 0.032, n 18). not the mix.
- skeptic
- leave-one-out range -0.59 to -0.42, sign flips 0; without severely affected donors -0.49 (p 0.040, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.77 (p 1.7e-4, n 18) vs -0.49 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GALNT6 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GALNT6 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.47 p 0.091 (needs p < 1.7e-4)
Receipts
loading the receipts